|
Precancerous conditions
|
Age ≤ 40 years
|
Reference
|
–
|
Reference
|
–
|
|
Age between 41 and 50 years
|
10.77 (4.59–25.26)
|
0.001
|
10.78 (4.54–25.59)
|
0.001
|
|
Age between 51 and 60 years
|
11.35 (4.84–26.57)
|
0.001
|
9.88 (4.18–23.35)
|
0.001
|
|
Age ≥ 61 years
|
19.01 (8.24–43.86)
|
0.001
|
18.53 (7.94–43.26)
|
0.001
|
|
NSAID consumption
|
0.34 (0.20–0.58)
|
0.001
|
0.34 (0.19–0.60)
|
0.001
|
|
H. pylori infection
|
4.33 (2.05–9.16)
|
0.001
|
4.01 (1.83–8.78)
|
0.001
|
|
Abnormal gastric biopsy
|
Age between 41 and 50 years
|
2.55 (1.39–4.67)
|
0.002
|
2.32 (1.22–4.39)
|
0.01
|
|
Age between 51 and 60 years
|
2.52 (1.38–4.63)
|
0.003
|
2.16 (1.14–4.08)
|
0.01
|
|
Age ≥ 61 years
|
3.49 (1.79–6.81)
|
0.001
|
3.28 (1.63–6.60)
|
0.001
|
|
H. pylori infection
|
6.29 (3.94–10.01)
|
0.001
|
5.92 (3.67–9.55)
|
0.001
|
|
Atrophy
|
Age between 41 and 50 years
|
12.47 (2.76–56.25)
|
0.001
|
11.96 (2.64–52.20)
|
0.001
|
|
Age between 51 and 60 years
|
23.19 (5.35–100.56)
|
0.001
|
20.19 (4.64–87.90)
|
0.001
|
|
Age ≥ 61 years
|
45.82 (10.80–194.30)
|
0.001
|
43.29 (10.16–184.33)
|
0.001
|
|
NSAID consumption
|
0.37 (0.19–0.73)
|
0.004
|
0.40 (0.20–0.82)
|
0.012
|
|
H. pylori infection
|
3.1 (1.31–7.35)
|
0.01
|
2.72 (1.10–6.71)
|
0.029
|
|
Metaplasia
|
Age between 41 and 50 years
|
7.6 (2.76–20.92)
|
0.001
|
7.31 (2.63–20.29)
|
0.001
|
|
Age between 51 and 60 years
|
10.18 (3.77–27.47)
|
0.001
|
8.75 (3.22–23.79)
|
0.001
|
|
Age ≥ 61 years
|
21.00 (8.01–55.00)
|
0.001
|
20.00 (7.57–52.84)
|
0.001
|
|
NSAID consumption
|
0.35 (0.19–0.66)
|
0.001
|
0.37 (0.19–0.71)
|
0.003
|
|
H. pylori infection
|
3.94 (1.67–9.27)
|
0.002
|
3.58 (1.47–8.72)
|
0.005
|
|
Dysplasia
|
Age between 41 and 50 years
|
15.77 (3.56–69.87)
|
0.001
|
16.29 (3.66–72.38)
|
0.001
|
|
Age between 51 and 60 years
|
8.40 (1.78–39.57)
|
0.013
|
7.65 (1.62–36.11)
|
0.013
|
|
Age ≥ 61 years
|
19.45 (4.44–85.11)
|
0.001
|
18.64 (4.25–81.79)
|
0.001
|
|
NSAID consumption
|
0.33 (0.13–0.80)
|
0.014
|
0.33 (0.13–0.82)
|
0.017
|
